Table 1.
Demographic and clinical characteristics of the 102 patients.
| Characteristics | All patients (102) | cVM (39) | sVM (49) | Non-VM (14) | P-value | P1 | P2 |
|---|---|---|---|---|---|---|---|
| Age (median, IQR, years) | 41 (29, 55) | 45 (39, 57) | 41 (29, 55) | 30 (15, 40) | 0.03 | <0.01 | 0.07 |
| Gender (male, %) | 59 (57.84%) | 22 (56.41%) | 26 (53.06%) | 11 (78.57%) | 0.25 | 0.20 | 0.13 |
| Hypertension | 18 (17.65%) | 10 (25.64%) | 7 (14.28%) | 1 (7.14%) | 0.26 | 0.25 | 0.67 |
| Diabetes mellitus | 2 (1.96%) | 1 (2.46%) | 1 (2.04%) | 0 (0%) | 1.00 | 1.00 | 1.00 |
| Fever (b.t >38°C) | 23 (22.55%) | 13 (33.33%) | 8 (16.32%) | 2 (14.28%) | 0.14 | 0.30 | 1.00 |
| LOS (median, IQR) | 20.5 (15, 27) | 24(16, 31) | 18 (15, 24) | 22.5 (18, 27) | 0.04 | 0.75 | 0.12 |
| Time of cure of infection (median, IQR) | 6 (3, 10.5) | 6 (3, 11) | 4 (1, 5) | 6.5 (3.5, 12.0) | 0.37 | 0.88 | 0.21 |
| GCS (median, IQR) | 5 (4, 9) | 5 (4.0, 10.5) | – | 7.1 (7.1, 7.1) | 0.70 | 0.70 | – |
| CSF leakage | 11 (10.78%) | 4 (10.25%) | 7 (14.28%) | 0 (0%) | 0.45 | 0.56 | 0.33 |
| Craniotomy | 70 (68.63%) | 18 (46.15%) | 39 (79.59%) | 13 (92.85%) | <0.01 | <0.01 | 0.43 |
| Surgical wound classification | 0.78 | 1.00 | 1.00 | ||||
| Clean (I) | 64 (62.75%) | 26 (66.67%) | 29 (59.18%) | 9 (64.29%) | |||
| Clean-contaminate (II) | 38 (37.25%) | 13 (33.33%) | 20 (40.82%) | 5 (35.71%) | |||
| Reoperation | 15 (14.71%) | 10 (25.64%) | 3 (6.12%) | 2 (14.29%) | 0.03 | 0.48 | 0.31 |
| Assist mechanical ventilation | 15 (14.71%) | 13 (33.33%) | 0 (0%) | 2 (14.29%) | <0.01 | 0.30 | 0.05 |
| Tumor | 80 (78.43%) | 31 (79.49%) | 37 (75.51%) | 12 (85.71%) | 0.85 | 1.00 | 0.72 |
| ICU admission | 29 (27.88%) | 14 (35.89%) | 11 (22.45%) | 4 (28.57%) | 0.37 | 0.75 | 0.73 |
| Bacteremia | 5 (4.90%) | 5 (12.82%) | 0 (0%) | 0 (0%) | 0.02 | 0.31 | \ |
| Hospital-acquired pneumonia | 8 (7.84%) | 6 (15.38%) | 1 (2.04%) | 1 (7.14%) | 0.05 | 0.66 | 0.40 |
| Mortality | 2 (1.96%) | 2 (5.13%) | 0 (0%) | 0 (0%) | 0.40 | 1.00 | \ |
| Antibiotics | |||||||
| Antibiotic prophylaxis | 84 (82.35%) | 36 (92.31%) | 36 (73.47%) | 12 (85.71%) | 1.00 | 0.60 | 0.49 |
| Empirical therapy | 91 (89.22%) | 35 (89.73%) | 43 (87.76%) | 13 (92.86%) | 1.00 | 1.00 | 1.00 |
| Definitive therapy | 82 (80.39%) | 37 (94.87%) | 34 (69.38%) | 11 (78.57%) | <0.01 | 0.11 | 0.74 |
| C-cell/μl (median, IQR) | 3,841.5 (1,432, 8,897) | 3,186 (671, 8,109) | 4,671 (2,548, 14,442) | 806.5 (125, 3,695) | <0.01 | 0.07 | <0.01 |
| C-leu/μl (median, IQR) | 1,577.5 (289, 3,651) | 586 (242, 2,110) | 2,310 (1,632, 4,396) | 171.5 (51,535) | <0.01 | <0.01 | <0.01 |
| C-neu% (median, IQR) | 83.45 (74.5, 89.3) | 84 (66.9, 89.3) | 85.7 (79.6, 89.9) | 65.5 (27.7, 83.6) | 0.01 | 0.07 | <0.01 |
| C-pro mg/dl (median, IQR) | 121.305 (84.58, 212.03) | 112.2 (84.6, 230.8) | 139.6 (94.9, 194.9) | 81.4 (65.8, 191.5) | 0.12 | 0.17 | 0.04 |
| C-Cl mmol/L (median, IQR) | 119.5 (115, 123) | 121.0 (115.0, 125.0) | 118.7 (114.7, 120.6) | 120.6 (117.3, 123.8) | 0.16 | 0.81 | 0.20 |
| C-GLU mmol/L (median, IQR) | 2.4 (1.65, 3.15) | 2.6 (1.9, 3.7) | 2.1 (1.4, 3.1) | 2.6 (1.2, 3.1) | 0.14 | 0.44 | 0.83 |
| C-lac mmol/L (median, IQR) | 5.35 (3.8, 6.3) | 5.4 (3.4, 7.0) | 5.5 (4.8, 6.3) | 4.6 (2.4, 5.3) | 0.10 | 0.14 | 0.03 |
| B-leu mg/L (median, IQR) | 11.84 (9.02, 14.97) | 11.7 (8.8, 15.3) | 11.9 (9.2, 15.0) | 12.1 (8.2, 14.1) | 0.92 | 0.83 | 0.95 |
| B-glu mmol/L (median, IQR) | 6.13 (5.22, 7.38) | 6.1 (5.0, 8.0) | 6.3 (5.3, 7.4) | 5.9 (5.3, 7.0) | 0.79 | 0.98 | 0.62 |
| B-neu% (median, IQR) | 8.85 (7.15, 12.19) | 8.9 (7.0, 12.2) | 8.7 (7.5, 12.4) | 9.4 (5.7, 11.8) | 0.93 | 0.98 | 0.91 |
| C/B-glu (median, IQR) | 0.36 (0.2, 0.49) | 0.4 (0.3, 0.6) | 0.4 (0.2, 0.4) | 0.4 (0.2, 0.5) | 0.30 | 0.32 | 0.88 |
| PCT (median, IQR) | 0.11 (0.0, 0.59) | 0.1 (0.0, 0.7) | 0.1 (0.0, 0.1) | – | 0.92 | – | – |
P1, Comparison between cVM and nVM; P2, Comparison between sVM and nVM.